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Yu Wang1 and Shuangge Ma2*Abstract
Background: MCL (mantle cell lymphoma) is a rare subtype of NHL (non-Hodgkin lymphoma) with mostly poor
prognosis. Different races have different etiology, presentation, and progression patterns.
Methods: Data were analyzed on MCL patients in the United States reported to the SEER (Surveillance,
Epidemiology, and End Results) database between 1992 and 2009. SEER contains the most comprehensive
population-based cancer information in the U.S., covering approximately 28% of the population. Racial groups ana-
lyzed included non-Hispanic whites, Hispanic whites, blacks, and Asians/PIs (Pacific Islanders). Patient characteristics,
age-adjusted incidence rate, and survival rate were compared across races. Stratification by age, gender, and stage
at diagnosis was considered. Multivariate analysis was conducted on survival.
Results: In the analysis of patients’ characteristics, distributions of gender, marital status, age at diagnosis, stage,
and extranodal involvement were significantly different across races. For all three age groups and both male and
female, non-Hispanic whites have the highest incidence rates. In the analysis of survival, for cancers diagnosed in
the period of 1992–2004, no significant racial difference is observed. For cancers diagnosed in the period of
1999–2004, significant racial differences exist for the 40–64 age group and stage III and IV cancers.
Conclusions: Racial differences exist among MCL patients in the U.S. in terms of patients’ characteristics,
incidence, and survival. More extended data collection and analysis are needed to more comprehensively
describe and understand the racial differences.
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NHL (non-Hodgkin lymphoma) has over 30 subtypes,
with different subtypes having different clinical and mo-
lecular features [1]. MCL (mantle cell lymphoma) is a
rare subtype of NHL. It was proposed as a distinct entity
in 1992 [2] and accepted by the Revised European American
Classification for Lymphoma (REAL) in 1994. The symp-
toms of MCL include swelling, loss of appetite and fatigue,
night sweats, fevers, and weight loss. Diagnosis of MCL usu-
ally requires removing an enlarged lymph node and examin-
ing the cells under a microscope. MCL comprises about 6%
of all NHL cases [3]. Its age-adjusted incidence rate is about
0.51 to 0.55 per 100,000 person-years. In the U.S., the inci-
dence of MCL had been increasing between 1992 and 2007
[4,5], and there are currently about 15,000 MCL patients in* Correspondence: shuangge.ma@yale.edu
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unless otherwise stated.total. These patients are typically Caucasian, male, and
elderly. Multiple risk factors have been suggested as
associated with the risk of developing MCL, including
lifestyle and occupational risk factors, viruses, family
history, and molecular risk factors [6]. For MCL patients,
the standard first-line treatment consists of rituximab
(a chimeric monoclonal anti-CD20 antibody, approved
by U.S. FDA in 1997) in combination with chemother-
apy [7]. Other treatment options include other monoclo-
nal antibody therapy, stem cell transplants, radiotherapy,
steroid therapy, and relatively newer drugs such as Tem-
sirolimus, Lenalidomide, and Bortezomib. Most MCLs
have an aggressive clinical course with a median survival
of 3–7 years [8]. Multiple factors influence MCL progno-
sis. Shorter overall survival has been associated with older
age, worse ECOG (Eastern Cooperative Oncology Group)
performance status, higher LDH (Lactate dehydrogenase),
higher white blood cell count [9], and advanced diseasesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Wang and Ma BMC Cancer 2014, 14:764 Page 2 of 8
http://www.biomedcentral.com/1471-2407/14/764[10]. Multiple genetic factors have also been implicated in
MCL prognosis.
The goal of this study, different from that of many
published ones, is to comprehensively investigate the ra-
cial differences among MCL patients in the U.S., in
terms of patients’ characteristics, clinical-pathologic fea-
tures, incidence, and survival rates. Racial differences in
multiple clinical and epidemiologic aspects for some other
cancer types and other NHL subtypes, such as DLBCL
(diffuse large B-cell lymphoma) and follicular lymphoma,
have been studied [11-18]. However, research on MCL re-
mains scarce. The existing MCL studies have limitations
by focusing on specific racial groups or specific outcomes.
For example, Chim and others [19] compared only
Chinese and Caucasians; and Zhou and others [4] fo-
cused on incidence rates. This article targets filling the
knowledge gap by comprehensively comparing non-
Hispanic whites, Hispanic whites, blacks, and Asians/
PIs (Pacific Islanders) in multiple aspects of MCL.
Methods
Source population
The population-based sample was obtained from the SEER
(Surveillance, Epidemiology, and End Results, http://seer.
cancer.gov/) database. All data analyzed in this study
are publicly available. SEER is the most comprehensive
population-based cancer database in the U.S., contain-
ing data from 18 regional and state registries. It has
multiple registry groupings for analyses. Different registry
groupings cover different numbers of regions and time pe-
riods. More details are available at http://seer.cancer.gov/
registries/terms.html. SEER 9, 13, and 18 registries, which
are analyzed in this article, cover approximately 9.5%,
14%, and 28.0% of the U.S. population, respectively. For
each MCL case, the first matching record was selected for
analysis. The International Classification of Diseases for
Oncology (ICD-O)-3 code used for MCL was 9673. In
data examination, we found 16 patients with T-cell MCL
and 5 patients with null-cell MCL. Such samples were re-
moved from analysis. All SEER registries were included in
the analysis.
Different SEER registry groupings were used to maximize
sample size. Specifically, for the analysis of patients’ charac-
teristics and clinical-pathologic features, SEER 9 contains
data on cancers diagnosed between 1973 and 2009. For in-
cidence, SEER 13 data, which include detailed race and in-
cidence information for cancers diagnosed between 1992
and 2009, are analyzed. And for survival, SEER 18 has data
for cancers diagnosed between 1973 and 2004 and followed
up to 12/31/2009. As the current definition of MCL was
not established until 1992, we limited our analysis to all
cancers diagnosed after 1992. Rituximab was introduced in
1997, is now the standard first-line treatment, and has a
significant effect on survival. Thus, we also conductedsurvival analysis on cancers diagnosed after 1999 [20].
Clinical-pathologic features analyzed include gender,
marital status (single, married, and separated/divorced/
widowed), age at diagnosis, stage (I, II, III, and IV, accord-
ing to the Ann Arbor staging system), B symptoms
(no, yes, and unknown), extranodal involvement (no
and yes), and survival time. The main outcomes of interest
are incidence rate and survival rate.Statistical analysis
In the comparison of patient characteristics and clinical-
pathologic features across racial groups, Chi-squared
tests and ANOVA were used, and p-values were com-
puted. The analysis was conducted using SAS version 9.2.
Age-adjusted incidence rates were calculated with SEER*-
Stat using U.S. 2000 Census data for age-standardization.
Five-year relative survival rates were calculated with
SEER*Stat using an actuarial method, which accommo-
dates the right-censored nature of survival data [21].
Multivariate Cox regressions were then conducted, adjust-
ing for age at diagnosis, gender, marital status, B symp-
toms, and extranodal involvement, and stratified by stage
at diagnosis.Results
Patients’ characteristics and clinical-pathologic features
A total of 2,958 MCL patients were identified in SEER
between 1992 and 2009 (Table 1). There are overall
more male patients (67.2%). The gender distributions are
different across races (p-value = 0.043), with Hispanic
whites having the most male patients (70.6%) and blacks
having the least (56.2%). Most MCL patients are married
(68.4%). Different racial groups have significantly differ-
ent marital status (p-value < 0.001). Among Asian/PI pa-
tients, 74.8% are married. In contrast, only 42.9% of
black patients are married. The age at diagnosis is also
significantly different across races (p-value < 0.001). For
non-Hispanic whites, the mean age at diagnosis is 68.2,
compared to 62.8 for blacks. Most MCLs are diagnosed
at late stages. In our analysis, 62.3% are stage IV, and
14.7% are stage III. The racial difference is significant
(p-value-0.029), with for example 63.2% of non-Hispanic
whites and 53.5% blacks having stage IV. The distribution
of B symptoms shows no racial difference. Overall, 16.2%
have extranodal involvement, and the racial difference is
significant (p-value < 0.001). Asians/PIs have the highest
percentage of extranodal involvement. Most patients did
not receive surgery or radiation (59.8%). There is no sig-
nificant racial difference. The median survival time is
46.0 months. Hispanic whites have the longest median
survival (57.0 months), while blacks having the shortest
(39.0 months). However, the racial difference is not
significant.
Table 1 MCL patients’ characteristics and clinical-pathologic features for the whole cohort and different racial groups








Male 1989 (67.2) 1775 (67.7) 77 (70.6) 68 (56.2) 69 (63.9)
Female 969 (32.8) 845 (32.3) 32 (29.4) 53 (43.8) 39 (36.1)
Marital Status <0.001
Single 243 (8.7) 195 (7.9) 20 (20.8) 21 (18.8) 7 (6.8)
Married 1905 (68.4) 1721 (69.6) 59 (61.5) 48 (42.9) 77 (74.8)
Separated/divorced/widowed 636 (22.8) 557 (22.5) 17 (17.7) 43 (38.4) 19 (18.4)
Age at diagnosis 67.8 ± 12.3 68.2 ± 12.1 64.3 ± 12.7 62.8 ± 13.7 67.0 ± 12.1 <0.001
Stage 0.029
Stage I 396 (14.1) 338 (13.6) 20 (20.2) 18 (15.8) 20 (18.7)
Stage II 251 (8.9) 219 (8.8) 8 (8.1) 9 (7.9) 15 (14.0)
Stage III 411 (14.7) 357 (14.4) 17 (17.2) 26 (22.8) 11 (10.3)
Stage IV 1747 (62.3) 1571 (63.2) 54 (54.5) 61 (53.5) 61 (57.0)
B symptoms 0.108
No 1070 (36.2) 949 (36.2) 47 (43.1) 36 (29.8) 38 (35.2)
Yes 596 (20.1) 513 (19.6) 23 (21.1) 35 (28.9) 25 (23.1)
Unknown 1292 (43.7) 1158 (44.2) 39 (35.8) 50 (41.3) 45 (41.7)
Extranodal involvement <0.001
No 2478 (83.8) 2206 (84.2) 93 (85.3) 106 (87.6) 73 (67.6)
Yes 480 (16.2) 414 (15.8) 16 (14.7) 15 (12.4) 35 (32.4)
Survival time (month) (Median ± SD) 46.0 ± 1.8 46.0 ± 1.9 57.0 ± 13.5 39.0 ± 7.9 46.0 ± 6.8 0.735
Cancers diagnosed between 1992 and 2009 in the SEER 9 database. For a continuous variable, mean ± standard deviation, and for a categorical variable,
count (percentage).
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The overall age-adjusted incidence rate is 0.64 per
100,000 person-years (Table 2). Incidence increases with
age. The three age groups have incidence rates 0.01, 0.73,
and 3.22, respectively. Overall, non-Hispanic whites have
the highest incidence rate (0.73, 95% CI 0.71-0.76), signifi-
cantly higher than those of the other races. For the <40
age group, the incidence rates are low for all races. For the
40–64 and 65+ age groups, non-Hispanic whites have the
highest incidence rates, followed by Hispanic whites.
Asians/PIs have the lowest rates. Overall, males have a
higher incidence rate (0.98, 95% CI 0.94-1.02) than fe-
males (0.37, 95% 0.35-0.39). For both male and female,
non-Hispanic whites have the highest incidence rates,
followed by Hispanic whites and then blacks.
Survival
For cancers diagnosed in the period of 1992–2004, the
five-year relative survival rates are shown in Table 3.
When stratified by age, for the <40 years group, Asians/
PIs have the best five-year survival rate (100%), whereas
blacks having the worst (45.5%). For the 40–64 years
group, non-Hispanic whites have the best survival rate(63.1%), while Hispanic whites have the worst (51.4%).
For the 65+ years group, non-Hispanic whites have the
best survival rate (44.4%), while blacks have the worst
(34.9%). The racial differences are not significant in
the multivariate analysis (detailed results are shown in
Additional file 1: Table S4). When stratified by gender,
for male, non-Hispanic whites have the best survival
rate, and Hispanic whites have the worst. For female,
Asians/PIs have the best survival rate, and Hispanic
whites still have the worst. The racial differences are
not significant in multivariate analysis. When stratified
by stage at diagnosis, for stage I-III, Asians/PIs have
the best survival, followed by non-Hispanic whites.
Hispanic whites have the worst survival. The racial dif-
ferences are not significant. Again these results should
be taken cautiously because of the small sample sizes.
For stage IV, the racial difference is borderline signifi-
cant in multivariate analysis (p-value = 0.063). In par-
ticular, non-Hispanic whites have the best survival rate
(49.0%), followed by blacks (45.4%). Figure 1 shows the
unadjusted survival rate for five years. In the first year,
the differences across races are ignorable. Between year
one and year three, there is no dominating racial group.
Table 2 Age-adjusted MCL incidence rates per 100,000 person-years for the whole cohort and different racial groups,
stratified by age and gender
Incidence Non-Hispanic white Hispanic white Black Asian/ PI Total
n IR (95% CI) n IR (95% CI) n IR (95% CI) n IR (95% CI) n IR (95% CI)




























































Diagnoses in the period of 1992–2009 in the SEER 13 database. In each cell, estimate (95% CI). Rates were age-adjusted using the U.S. 2000 Census population.
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and year five, with Hispanic whites having the worst and
non-Hispanic whites having the best survival.
For cancers diagnosed in the period of 1999–2004, the
survival analysis results are presented in Additional file 1:
Tables S5 and Table S6. When stratified by age, the ra-
cial difference is significant for the 40–64 years group
(p-value = 0.025). Specifically, non-Hispanic whites haveTable 3 Five-year relative survival rates for different racial gr
Total (n = 5438) Non-Hispanic white (n = 4458) Hispan
n Rate (95% CI) n Rate (95% CI) n
Age group















































Cancers diagnosed in the period of 1992–2004 and followed up to 12/31/2009 in th
generated from multivariate Cox models. Details are provided in Additional filethe best survival (64.4%), while Hispanic whites have the
worst (50.7%). When stratified by gender, the racial differ-
ence is borderline significant for female (p-value = 0.093),
with non-Hispanic whites having the best survival (54.0%)
and Hispanic whites having the worst (42.2%). When
stratified by stage at diagnosis, the racial differences
are significant for stage III and IV. In particular, for
stage III, Asians/PIs have the best survival, while Hispanicoups, stratified by age, gender, and stage at diagnosis
ic white (n = 446) Black (n = 241) Asian/PI (n = 219) P-value






























































e SEER 18 database. In each cell, estimated rate (95% CI). P-values were
1.
Figure 1 Relative survival up to five years for different racial
groups. Cancers diagnosed in the period of 1992–2004 and followed
up to 12/31/2009.
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have the best survival (50.5%), followed by blacks (44.7%).
Asians/PIs have the worst survival (38.7%).
Discussion
Main findings and possible interpretations
As a mostly aggressive variant of NHL, MCL has been
studied in multiple publications. However, most of the
existing studies have been focused on pathogenesis, inci-
dence trends, and survival patterns. In some studies,
race has been included as a confounding variable. A
small number of studies are concerned with racial differ-
ences, but in a much less systematic manner. In this
study, we have analyzed SEER data, comprehensively
compared non-Hispanic whites, Hispanic whites, blacks,
and Asians/PIs, and found that for MCL patients in the
U.S., racial differences exist in terms of patients’ charac-
teristics, clinical-pathologic features, incidence, and sur-
vival. As mentioned in Introduction, racial differences
have been examined for other cancer types and other
subtypes of NHL. It has been suggested in the literature
[22] that MCL differs from other NHL subtypes in many
aspects. Thus in this study, we have focused on MCL
without attempting to compare with findings on other
NHL subtypes.
The observed gender and age distributions are similar
to those in the literature. Our analysis suggests that the
distributions of gender, marital status, age at diagnosis,
stage, and extranodal involvement are different across
racial groups. The development of MCL is an extremely
complex process. The observed racial differences reflect
the complex interactions of genetic makeup, occupa-
tional exposures, infectious conditions, development of
autoimmune diseases, family history, and socioeconomic
status [23,24]. It is unclear if there is a direct linkbetween marital status and MCL. In the general popula-
tion, different racial groups have significantly different
marital status [25]. Specifically, according to the National
Healthy Marriage Resource Center, the percentages of
ever married are 72.6% (white men), 56.7% (black men),
66.6 (Asian men), 60.0% (Hispanic men), 79.3% (white
women), 58.1% (black women), 74.7% (Asian women), and
70.3% (Hispanic women). Thus the observed significant
marital status difference may or may not be relevant to
MCL.
In the incidence analysis, the <40 years age group has
a small sample size, and the analysis results should be
interpreted with extreme caution. Other groups have
moderate to large sample sizes, and the results can be
more reliable. The observed incidence rate is slightly
higher than that reported in the literature. Racial differ-
ences in MCL incidence have been studied in a few pub-
lications. Zhou and others [4] analyzed data on patients
diagnosed between 1992 and 2004, and concluded that
the incidence of MCL was higher in men than in women,
and higher in Caucasians than in blacks. Aschebrook-Kilfoy
and others [26] compared MCL incidence between
1992–1994 and 2005–2009, and found that the in-
crease in incidence was strongest for men and for
whites. Our analysis includes more racial groups and
also provides detailed results on three age groups.
Multiple factors are involved in the development of
MCL and NHL overall. However, there is a lack of
consensus [1,22,24]. Lifestyle risk factors have been
suggested as associated with NHL overall, and such
associations may differ across races [1]. For example,
it has been suggested that certain dietary intake [27]
and dietary patterns [28] have race-specific effects on
the risk of NHL. A challenge is that although the
aforementioned studies include MCL, because of small
sample sizes, MCL-specific analysis has not been con-
ducted. Recreational exposure to ultraviolet radiation and
occupational exposure to pesticides, solvents, and gasoline
also contribute to the incidence of MCL [29,30]. It has
been suggested that the racial differences in MCL is at
least partly confounded by occupation [31]. The develop-
ment of infectious diseases and immune suppression may
also contribute to MCL risk in a race-specific way. For ex-
ample, Koshiol and others [23] showed that blacks had a
higher risk of NHL associated with infections than whites
and a tendency toward higher risk associated with aller-
gies. The genetic hallmark of MCL is the t(11;14) (q13;
q32) translocation. Beyond this translocation, MCL tumor
cells may also carry a high number of secondary chromo-
somal and molecular alterations [24]. For NHL overall, it
has been suggested that the associations between genetic
variants and risk vary across races [32]. In addition, al-
though it is believed that most MCL cells carry the t
(11;14) translocation, a study on Chinese patients showed
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other genetic variations, the racial differences remain
to be explored. Another possible contributing factor
of the racial differences in incidence is the racial vari-
ation in diagnosis [34].
Racial differences in survival exist for many types of
cancers. For NHL overall, there has been progress in re-
ducing disparities in survival between non-Hispanic
whites and minorities [34]. MCL survival also depends
on multiple factors [22]. In our analysis on cancers diag-
nosed in the period of 1999–2004, when stratified by
age, the numbers of patients in the <40 years and 40–64
years groups are relatively small (Table 3). For the 65+
group, the unadjusted survival rates differ by as much as
9.5% (44.4% for non-Hispanic whites versus 34.9% for
Hispanic whites). However, the racial difference is not
significant in multivariate analysis. The lack of signifi-
cant difference is also observed for both male and fe-
male. When stratified by stage at diagnosis, the racial
difference is borderline significant for stage IV tumors.
Such difference may be caused by multiple factors. MIPI,
the MCL International Prognostic Index, contains four
variables, namely age, ECOG performance status, LDH/
ULN (upper limit of normal), and white blood cell counts
[9]. In Table 1, we observe significant racial differences in
age at diagnosis, which, according to MIPI, may contrib-
ute to the observed survival differences. In addition, white
blood cell counts also vary across races, for example,
blacks tend to have lower white blood cell counts than
Caucasians. Other possible prognostic factors include
Ki-67, MCL cell types, and Beta-2 microglobulin [35].
However such variables are not available in SEER and
cannot be accounted for. As with etiology, genetic changes
have also been implicated in prognosis [36,37]. The exist-
ing genetic studies usually have small sample sizes. To the
best of our knowledge, race has not been accounted for in
these studies. Another possible contributing factor is
treatment strategy—different racial groups can have
different treatments. More racial differences are observed
in the analysis of cancers diagnosed in the period of
1999–2004. In the literature, it has been suggested that
the incidence and clinical-pathologic features of MCL vary
over time. More importantly, the effect of rituximab and
other newer treatments on MCL survival has been noted
in multiple published studies.
Limitations
The SEER database is analyzed as it is the largest cancer
registry in the U.S. Even so, as can be seen from the ta-
bles, sample sizes for certain subsets are still small. In
addition, using SEER has the following limitations. With
multiple sites, errors may arise in tumor classification
and staging. However, we do not expect a series of sys-
tematic errors correlated with ethnicity. This study mayhave also been hindered by the multiple coexisting clas-
sification schemes. Patients diagnosed before 2001 may
have diagnosis codes from earlier ICD-O versions that
need to be converted to the ICD-O-3, which may have
resulted in a higher proportion of unclassified cases.
Clarke and others [38] compared computer-converted
ICD-O-3 codes with ICD-O-3 codes generated directly
from diagnostic pathology reports, and found that the
classification of MCL might have a reliability problem.
Furthermore, data collected in SEER may not be com-
prehensive enough. Quite a few variables that are poten-
tially associated with etiology and prognosis are not
available. Information on treatment is lacking. Newer
treatment regimens are not included, and there is no in-
formation on chemotherapy. In addition, insurance sta-
tus, socioeconomic status, and treatment availability,
which are relevant to treatment and so survival, are not
measured. All patients are from the U.S. In the literature
there are studies investigating the characteristics, inci-
dence, and survival of MCL in other countries and re-
gions [39-41]. A cross-region comparison is interesting
but beyond our scope. In data analysis, we have followed
published studies and simply used 0.05 as the p-value
cutoff for significance. In stratified analysis, multiple
comparison adjustment may be needed [42], which re-
sults in a stricter p-value cutoff.Conclusion
Analysis of the SEER data shows that racial differences
exist among MCL patients in the U.S. in terms of pa-
tients’ characteristics, incidence, and survival. Although
there are multiple possible explanations, the exact causes
of the observed differences remain to be identified. More
comprehensive data collection and analysis are needed
to fully decipher and interpret the racial differences.
Despite several limitations, findings in this study can be
informative to cancer epidemiologists, clinicians, and
policy-makers.Additional file
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